개방각 녹내장 시장 규모, 점유율 및 동향 분석 보고서 : 시술별, 유형별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Open Angle Glaucoma Market Summary

The global open angle glaucoma market size was valued at USD 1.0 billion in 2025 and is projected to grow from USD 1.1 billion in 2026 to USD 2.1 billion by 2033, at a CAGR of 9.6% from 2026 to 2033. The market in North America dominated with a revenue share of 41.4% in 2025. Open-angle glaucoma (OAG) is a major cause of irreversible vision loss worldwide, with its burden influenced by population aging, increasing life expectancy, and rising prevalence of myopia. The disease burden varies across regions due to differences in demographics, genetic predisposition, healthcare access, and disease detection rates. These epidemiological trends are expected to increase the need for glaucoma screening, diagnosis, monitoring, and treatment, thereby supporting sustained global demand for OAG-related medical and surgical interventions.

The open-angle glaucoma market is being supported by advances in diagnostic, monitoring, and therapeutic technologies, including optical coherence tomography (OCT), AI-enabled glaucoma screening, advanced visual field testing, minimally invasive glaucoma surgery (MIGS), and sustained drug-delivery solutions. Increasing adoption of these technologies enables earlier disease progression and personalized treatment planning while reducing dependence on conventional approaches. This trend is further supported by the growing global burden of glaucoma, population aging, and increasing emphasis on early diagnosis and long-term disease management to prevent irreversible vision loss.

Overall, the open-angle glaucoma market is supported by a combination of rising disease burden, aging populations, greater awareness of regular eye examinations, and continued technological advancements across diagnosis and treatment. This shift toward more proactive and technology-driven disease management is expected to remain an important factor shaping the market over the coming years.

Global Open Angle Glaucoma Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the open angle glaucoma market report on the basis of procedure, type, end use, and region:

• Procedure Outlook (Revenue, USD billion, 2021 - 2033)
• Bleb-based Procedures
  • Perforating (Fistulizing) Bleb-based Procedures
  • Non-Perforating Bleb-Based Procedures (NPDS)
• Non-Bleb-Based Procedures
• Type Outlook (Revenue, USD billion, 2021 - 2033)
• Standalone
• Combined
• End Use Outlook (Revenue, USD billion, 2021 - 2033)
• Inpatient
• Outpatient
• Regional Outlook (Revenue, USD billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
  • India
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Procedure
  • 1.2.2. Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Procedure outlook
  • 2.2.2. Type outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Open Angle Glaucoma Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Open Angle Glaucoma Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Open Angle Glaucoma Market: Procedure Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Open Angle Glaucoma Market: Procedure Movement Analysis
• 4.3. Open Angle Glaucoma Market by Procedure Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Bleb-based Procedures
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Perforating (Fistulizing) Bleb-based Procedures
    • 4.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Non-Perforating Bleb-Based Procedures (NPDS)
    • 4.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Non-Bleb-Based Procedures
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Open Angle Glaucoma Market: Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Open Angle Glaucoma Market: Type Movement Analysis
• 5.3. Open Angle Glaucoma Market by Type Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Standalone
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Combined
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Open Angle Glaucoma Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Open Angle Glaucoma Market: End Use Movement Analysis
• 6.3. Open Angle Glaucoma Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Inpatient
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Outpatient
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Open Angle Glaucoma Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Open Angle Glaucoma Market Movement Analysis
• 7.3. Open Angle Glaucoma Market: Regional Estimates & Trend Analysis by Procedure
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Europe
  • 7.5.6. Europe Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. UK
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. UK Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Germany
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement scenario
    • 7.5.8.5. Germany Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. France
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement scenario
    • 7.5.9.5. France Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.10. Italy
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Competitive Scenario
    • 7.5.10.3. Regulatory Framework
    • 7.5.10.4. Reimbursement scenario
    • 7.5.10.5. Italy Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.11. Spain
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Competitive Scenario
    • 7.5.11.3. Regulatory Framework
    • 7.5.11.4. Reimbursement scenario
    • 7.5.11.5. Spain Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.12. Denmark
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Competitive Scenario
    • 7.5.12.3. Regulatory Framework
    • 7.5.12.4. Reimbursement scenario
    • 7.5.12.5. Denmark Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.13. Sweden
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Competitive Scenario
    • 7.5.13.3. Regulatory Framework
    • 7.5.13.4. Reimbursement scenario
    • 7.5.13.5. Sweden Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.14. Norway
    • 7.5.14.1. Key Country Dynamics
    • 7.5.14.2. Competitive Scenario
    • 7.5.14.3. Regulatory Framework
    • 7.5.14.4. Reimbursement scenario
    • 7.5.14.5. Norway Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Japan Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. China Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. India Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. South Korea Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Australia Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Thailand Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Brazil Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Argentina Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. South Africa Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Saudi Arabia Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. UAE Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Kuwait Open Angle Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Glaukos Corporation
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Procedure benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Alcon Inc.
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Procedure benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Sight Sciences, Inc.
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Procedure benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Johnson & Johnson Vision Care, Inc.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Procedure benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. New World Medical, Inc.
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Procedure benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. IRIDEX Corporation
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Procedure benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Santen Pharmaceutical Co., Ltd.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Procedure benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Nova Eye Medical Limited
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Procedure benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. iSTAR Medical SA
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Procedure benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Carl Zeiss Meditec AG
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Procedure benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Lumenis Ltd.
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Procedure benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. ViaLase, Inc.
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Procedure benchmarking
    • 8.2.12.4. Strategic initiatives
  • 8.2.13. Lumibird SA
    • 8.2.13.1. Company overview
    • 8.2.13.2. Financial performance
    • 8.2.13.3. Procedure benchmarking
    • 8.2.13.4. Strategic initiatives
  • 8.2.14. Oertli Instrumente AG
    • 8.2.14.1. Company overview
    • 8.2.14.2. Financial performance
    • 8.2.14.3. Procedure benchmarking
    • 8.2.14.4. Strategic initiatives